Details for Patent: 4,058,552
Summary for Patent: 4,058,552
| Title: | Esters of p-carbonylphenoxy-isobutyric acids | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | This invention is concerned with esters of p-carbonylphenoxy-isobutyric acids of the general formulae: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Andre Mieville | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Orchimed SA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US05/600,127 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | # United States Patent 4,058,552: Fenofibrate Claim Scope, Expiration, and Patent Landscape U.S. Patent No. 4,058,552 covers a genus of substituted esters of p-carbonylphenoxy-isobutyric acid, including fenofibrate as the expressly claimed compound in claim 5. The patent issued on November 15, 1977, and its original 17-year U.S. patent term expired in 1994. It no longer creates an enforceable barrier to manufacture, sale, or use of fenofibrate in the United States. Current commercial protection has historically focused on micronized formulations, dissolution-enhanced compositions, dosage forms, and fenofibric-acid products rather than the expired active-ingredient patent. [1] What drug does U.S. Patent 4,058,552 protect?The patent protects a class of lipid-lowering compounds related to fenofibrate. Claim 5 identifies the key commercial molecule:
That compound is fenofibrate, chemically known as isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate. Fenofibrate is a prodrug that is hydrolyzed primarily to fenofibric acid. It is used with diet and other measures to treat dyslipidemia, including hypertriglyceridemia and mixed dyslipidemia. U.S. Food and Drug Administration labeling identifies fenofibrate as a peroxisome proliferator-activated receptor alpha agonist. [2] The patent’s commercial significance arose from three elements:
What are the principal claims in U.S. Patent 4,058,552?Claim 1: broad chemical genusClaim 1 covers esters of p-carbonylphenoxy-isobutyric acid having a substituted aromatic group and variable substituents represented by R, R', R", and Y. The relevant limitations are:
This is a Markush claim. It does not protect every lipid-lowering compound or every phenoxyisobutyric acid derivative. It protects compounds that satisfy the claimed structural variables and the connectivity shown in the patent’s chemical formula. The claim has two important boundaries:
Because the structural formula supplied in the question is represented only by an image placeholder, the textual variables alone do not establish every atom-to-atom relationship. The definitive scope depends on the formula printed in the issued patent. Claim 2: narrower subgenusClaim 2 narrows R to four chlorophenyl arrangements:
It narrows Y to:
Claim 2 therefore removes several alternatives from claim 1 and concentrates protection on chlorinated aromatic compounds with simple alkoxy groups. Claims 3 and 4: aromatic-substitution subclassesClaim 3 covers compounds in which R is 4-chlorophenyl. Claim 4 covers compounds in which R is 3,4-dichlorophenyl. These claims are narrower than claim 1 but do not, on their face, limit the complete compound to fenofibrate. Their scope remains subject to the other variables and the structural formula of claim 1. Claim 5: fenofibrateClaim 5 is the strongest commercial claim because it specifically names the fenofibrate structure:
This claim is narrower than the genus claims but provides a direct species claim to the principal marketed active ingredient. Claim 6: therapeutic compositionClaim 6 covers a pharmaceutical composition containing:
in a therapeutically effective amount for reducing blood cholesterol and lipid content. Claim 6 is a composition claim, not a conventional method-of-treatment claim. It does not expressly recite a particular tablet, capsule, particle-size distribution, dissolution profile, surfactant, or manufacturing process. When did U.S. Patent 4,058,552 expire?U.S. Patent 4,058,552 issued on November 15, 1977. For a patent of that vintage, the ordinary U.S. term was 17 years from issuance. On that basis, the patent expired on November 15, 1994. [1]
The patent predates the patent-term rules that generally calculate term from the earliest effective nonprovisional filing date. Patent-term adjustment and patent-term extension were not relevant in the modern sense to this original compound patent. The expiration eliminated exclusivity in the active ingredient. It did not automatically invalidate later patents covering formulations, dosage forms, manufacturing processes, or alternative active ingredients. What compounds fall within the patent’s claim scope?The patent’s claim structure reaches compounds with the following combination:
Fenofibrate is the most commercially important example because it uses:
The scope does not necessarily cover:
A product containing fenofibrate would have fallen within claim 5 during the patent term. A product containing a different fibrate would require a separate claim chart against the genus limitations. What is the Orange Book status of the patent?U.S. Patent 4,058,552 is not a current enforceable Orange Book barrier. Its claims expired decades ago. The FDA Orange Book lists patents associated with approved drug products, but listing does not extend an expired patent’s term. Orange Book relevance depends on the approved product, the applicable NDA, the patent’s expiration date, and whether the patent is still eligible for listing. [3] For fenofibrate products, later Orange Book-listed patents historically addressed pharmaceutical compositions and delivery characteristics, including formulation approaches designed to improve the dissolution and bioavailability of the poorly water-soluble active ingredient. Those patents were commercially more relevant to ANDA litigation than the expired 4,058,552 compound patent. The patent should therefore be classified as:
What formulation patents protected fenofibrate products?Fenofibrate has low aqueous solubility. Later product development focused on improving dissolution and absorption through particle-size reduction, micronization, excipients, wetting agents, and formulation design. Historically important fenofibrate formulation patents included patents associated with:
A frequently cited later patent is U.S. Patent No. 6,074,670, which concerned pharmaceutical compositions containing fenofibrate and was associated with later commercial formulation protection. [4] The legal scope of that patent was materially different from U.S. Patent 4,058,552 because it focused on composition and performance characteristics rather than claiming the original fenofibrate molecule as a chemical species. Fenofibrate formulation patents generally presented narrower but commercially practical claim strategies. A generic manufacturer could avoid a composition patent by using a different excipient system, particle-size profile, manufacturing process, or dosage form, provided the alternative did not satisfy the asserted claims. What method-of-use patents cover fenofibrate?U.S. Patent 4,058,552 does not appear, from the claims provided, to contain a conventional method-of-treatment claim such as administering fenofibrate to a patient to treat a specified disease. Claim 6 is directed to a composition. Its therapeutic purpose helps define the claimed composition, but the claim does not expressly require:
Later fenofibrate patents and regulatory exclusivities could address different clinical uses, formulations, or combinations. Those rights would need to be analyzed independently from the expired compound patent. Which companies challenged fenofibrate patents?Fenofibrate generated generic competition through ANDA filings after expiration of the original active-ingredient patent. Generic manufacturers and applicants included companies such as:
The precise litigants varied by product, dosage strength, formulation, and NDA. Litigation often centered on later formulation patents rather than U.S. Patent 4,058,552. Typical ANDA certifications included:
Once the original compound patent expired in 1994, Paragraph IV disputes shifted toward formulation patents and product-specific Orange Book listings. Under the Hatch-Waxman framework, a Paragraph IV notice could trigger patent litigation and a 30-month stay of FDA approval for the affected ANDA, subject to the statutory requirements. [5] How strong is the patent estate for fenofibrate?The original chemical patent was strong during its term because claim 5 directly covered fenofibrate and claim 1 potentially reached a broader group of related compounds. Its current strength is zero because it is expired. The historical estate can be assessed as follows:
The principal weakness of relying on the 4,058,552 patent today is expiration. The principal historical strength was the direct recitation of fenofibrate in claim 5. What generic entry risks exist for fenofibrate?Generic entry risk is high for products relying only on the fenofibrate active ingredient. The molecule is off patent, widely characterized, and available through multiple generic suppliers. Residual risks historically arose from:
A generic applicant using a formulation materially different from the branded product may reduce formulation-patent exposure but face separate FDA bioequivalence or clinical-performance requirements. For immediate-release oral fenofibrate products, the regulatory pathway is generally an ANDA where the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. [3] How does fenofibrate compare with other fibrates?
Fenofibrate’s commercial differentiation historically depended less on the original molecule and more on formulation performance, dosing convenience, triglyceride efficacy, and coadministration with statins. What licensing and commercial rights affected fenofibrate?The patent was associated with the original European pharmaceutical development of fenofibrate and later commercialization by companies including Fournier and Abbott Laboratories. Abbott acquired Fournier-related assets and marketed Tricor in the United States. AbbVie later became the relevant successor company for Abbott’s pharmaceutical business. The commercial rights should be separated into:
Expiration of U.S. Patent 4,058,552 did not terminate trademarks such as Tricor, nor did it eliminate proprietary know-how relating to particle engineering, manufacturing controls, or formulation scale-up. What litigation status applies to U.S. Patent 4,058,552?No current infringement litigation can be based on an expired patent for prospective commercial activity. Any historical litigation involving this patent would have concerned activity during its enforceable term and could have included validity, infringement, inventorship, patent-term, or regulatory-entry issues. Later fenofibrate litigation generally involved:
A historical settlement involving a later formulation patent would not revive or extend the term of U.S. Patent 4,058,552. Key Takeaways
FAQsDoes U.S. Patent 4,058,552 cover fenofibric acid?No. The patent expressly claims fenofibrate in claim 5, which is an isopropyl ester. Fenofibric acid is the corresponding hydrolyzed acid and requires separate claim coverage. Can a company manufacture fenofibrate without a license today?Yes, U.S. Patent 4,058,552 expired in 1994. A manufacturer must still address other enforceable patents, FDA requirements, trademarks, and applicable regulatory obligations. Is fenofibrate still protected by patents?The original fenofibrate molecule is no longer protected by the ’552 patent. Product-specific formulation, dosage-form, process, or fenofibric-acid patents must be assessed separately. Did claim 6 create a method-of-treatment patent?No. Claim 6 is drafted as a pharmaceutical composition claim. It identifies a therapeutic purpose but does not recite a standalone patient-treatment method. Does patent expiration eliminate FDA exclusivity?No. Patent expiration and FDA regulatory exclusivity are separate legal regimes. A product can have no blocking patent and still be subject to a regulatory exclusivity period applicable to a particular NDA or indication. References
More… ↓ |
Drugs Protected by US Patent 4,058,552
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 4,058,552
International Family Members for US Patent 4,058,552
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Belgium | 742484 | ⤷ Start Trial | |||
| Belgium | 790026 | ⤷ Start Trial | |||
| Brazil | 7016496 | ⤷ Start Trial | |||
| Canada | 960670 | ⤷ Start Trial | |||
| Switzerland | 515873 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
